scholarly journals The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care ◽  
2019 ◽  
Vol 42 (5) ◽  
pp. 767-776 ◽  
Author(s):  
Jarvis C. Noronha ◽  
Stephanie K. Nishi ◽  
Catherine R. Braunstein ◽  
Tauseef A. Khan ◽  
Sonia Blanco Mejia ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Cardiometabolic Risk ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Liquid Meal ◽  
Randomized Controlled ◽  
Meal Replacements

Effect of Liquid Meal Replacements on Cardiometabolic Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2018 ◽  
Vol 42 (5) ◽  
pp. S31-S32
Author(s):  
Jarvis C. Noronha ◽  
Stephanie K. Nishi ◽  
Catherine R. Braunstein ◽  
Tauseef A. Khan ◽  
Sonia Blanco Mejia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Cardiometabolic Risk ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Liquid Meal ◽  
Randomized Controlled ◽  
Meal Replacements

scholarly journals Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 12 ◽  
Author(s):  
Peyman Nowrouzi-Sohrabi ◽  
Negin Soroush ◽  
Reza Tabrizi ◽  
Mojtaba Shabani-Borujeni ◽  
Shahla Rezaei ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Cardiometabolic Risk ◽  
Meta Analysis ◽  
Risk Profile ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Artery Disease

Background: Whether liraglutide use improves cardiometabolic risk factors in different subsets of subjects with coronary artery disease (CAD) remains unclear. In a systematic review and meta-analysis, we quantified the effects of liraglutide on cardiometabolic risk profile in subjects with CAD with or without type 2 diabetes mellitus (T2D).Methods: Online database searches were conducted in PubMed, Scopus, EMBASE, Web of Science, Cochrane library, and Google Scholar from incept up to 15th January 2021. We identified randomized controlled trials (RCTs) assessing the effects of liraglutide compared to placebo on cardiometabolic risk profile. We used the random- or fixed-effect models to pool the weighted mean differences (WMDs) and 95% confidence intervals (CIs).Results: Out of a total of 7,320 citations, six articles (seven RCTs) with 294 subjects with CAD (mean age, 61.21 years; 19% women) were included. Our findings presented as WMD and 95% CI showed a statistical significant decrease in hemoglobin A1c (HbA1c) [−0.36%; −0.47; −0.26, p < 0.001; I2 = 0.0% (with 6 RCTs)], body mass index (BMI) [−0.61 kg/m2; −1.21; −0.01, p = 0.047; I2 = 72.2% (with five RCTs)], and waist circumference [−2.41 cm; −3.47; −1.36, p < 0.001; I2 = 0.0% (with three RCTs)]. Through a set of subgroup analyses, we found a significant reduction in BMI in CAD patients with T2D [WMD = −1.06; 95% CI, −1.42, −0.70, p < 0.001; I2 = 0.0% (with three RCTs)] compared to CAD only patients [WMD = −0.08; 95% CI, −0.45, 0.29, p = 0.66; I2 = 0.0% (with two RCTs)] in the liraglutide group compared with the placebo group. No significant changes in heart rate, blood pressure, and lipid profiles were observed.Conclusions: Among people with established CAD, liraglutide significantly improved HbA1c, BMI, and waist circumference values. The effect of liraglutide on BMI was more robust in individuals with T2D compared to those without.

Sign in / Sign up

Export Citation Format

Share Document